Acrivon Therapeutics Unveils Key Data at Two Major Conferences
Acrivon Therapeutics Showcases AP3 Platform at Leading Conferences
Acrivon Therapeutics, Inc. is set to demonstrate its innovative AP3 platform at two prominent scientific conferences within the upcoming days. This promising platform plays a pivotal role in the streamlined drug discovery and clinical advancement, particularly for its leading candidates, ACR-368 and ACR-2316.
Understanding the AP3 Platform
The Acrivon Predictive Precision Proteomics (AP3) platform represents a sophisticated approach in precision medicine aimed at identifying clinical biomarkers. This capability has been crucial for ACR-368, which is entering a Phase 2b study. The OncoSignature assay developed through AP3 has shown statistically significant results in validating patient responses. ACR-2316, also enabled by the AP3 compilation, demonstrates remarkable potential as a WEE1/PKMYT1 inhibitor with superior activity observed in initial studies.
Importance of Upcoming Presentations
At the Human Proteome Organization (HUPO) World Congress and the EORTC-NCI-AACR Symposium, Acrivon scientists will share their findings, highlighting how AP3 empowers clinical development. According to Kristina Masson, Ph.D., Acrivon’s dedication to harnessing cutting-edge technology has led to compelling discoveries that aid in overcoming challenges in biomarker discovery and tumor treatment resistance.
Details of Presentations
The following details outline the upcoming presentations at the HUPO 2024 World Congress:
- Title: Acrivon Predictive Precision Proteomics (AP3)-guided development and prospective clinical registrational-intent Phase 2 validation of the response-predictive OncoSignature test for ACR-368
- Session: Clinical Proteomics I
- Session Date and Time: Presentation scheduled for October 21, from 1:15 p.m. – 3:15 p.m. CEST
- Poster ID Number: P-I-0346
- Abstract Number: 525
Additionally, the ACR-2316 presentation is scheduled as follows:
- Title: ACR-2316: a potent, selective WEE1/PKMYT1 inhibitor rationally designed for superior single agent activity using Acrivon Predictive Precision Proteomics (AP3)
- Session: Clinical Proteomics II
- Session Date and Time: October 22, from 1:00 p.m. – 3:00 p.m. CEST
- Poster ID Number: P-II-0624
- Abstract Number: 513
ENA 2024 Symposium Presentation Features
At the ENA 2024 Symposium, Acrivon will also present details about ACR-2316:
- Title: Rational design of ACR-2316, a novel, potent WEE1/PKMYT1 inhibitor with superior single agent activity using Acrivon Predictive Precision Proteomics (AP3)
- Session Title: DNA Repair Modulation
- Session Date and Time: October 25, from 9:00 a.m. – 3:00 p.m. CEST
- Poster Board Number: PB318
Acrivon’s Commitment to Innovation
Acrivon Therapeutics is focused on developing precision oncology treatments tailored to individual patient profiles. Their proprietary platform, AP3, enables the measurement of compound-specific actions on tumor signaling and resistance mechanisms. This technology not only optimizes drug development but also assists in identifying patients best suited for these therapies.
Currently, Acrivon is advancing ACR-368, a selective small molecule inhibitor aimed at CHK1 and CHK2, currently in a potentially registrational Phase 2 trial for various tumors. The company has gained Fast Track designation from the FDA, which marks a significant milestone in its ongoing clinical journey. Results from recent studies highlight a confirmed overall response rate and compelling data on patient selection based on the OncoSignature test.
Looking Ahead
As Acrivon continues navigating the complexities of drug development, the outcomes and insights gleaned from its advanced presentations are expected to be instrumental in fostering innovation within the biopharmaceutical industry. The unique applications of the AP3 platform signal exciting possibilities not only for Acrivon’s therapies but also for the future of personalized medicine.
Frequently Asked Questions
What is the AP3 platform used for?
The AP3 platform is used for drug discovery and clinical development, helping identify biomarkers and optimize treatment designs.
When will the presentations take place?
The presentations will occur on October 21 and 22, 2024, at the HUPO World Congress and on October 25, 2024, at the ENA 2024 Symposium.
What are the key candidates being discussed?
The candidates discussed include ACR-368 and ACR-2316, two innovative treatments in cancer therapy.
What achievements has Acrivon made with ACR-368?
Acrivon has gained Fast Track designation from the FDA and has reported positive clinical data in its trials for ovarian and endometrial cancer.
How does Acrivon help tailor treatments for patients?
Acrivon utilizes its proprietary AP3 platform to match patients to treatments based on predicted sensitivity, enhancing personalized medicine approaches.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- AM Best Secures Constitution Insurance Company’s Ratings Amid Growth
- Governments Celebrate New Housing Initiative in Québec
- Investigation into NARSTCO, LLC's Recent Data Breach Incident
- Investigation into Action Automatic Sprinkler, Inc. Data Breach
- Innovative Alliance Between HealthRev and Trella Strengthens Care Agencies
- Foundation Source Strengthens Portfolio with Vennfi Acquisition
- Concerns Arise Over Zuora's Buyout Deal and Its Implications
- Optimizing Enrollment Management in K-12 Education Today
- Alpine 4 Technologies Stock Plunges to New Low - Key Insights
- Viant Technology Boosts Growth with New AI Tool Strategy
Recent Articles
- Potbelly Corporation Plans Q3 2024 Financial Result Call
- Fallow Grove Insurance Services Emerges as a Key Player in Market
- LM Funding America's Bitcoin Operations Approach Milestone Value
- Predicting Growth in the Fitness Equipment Industry by 2031
- Banzai Elevates Webinar Strategies with Salesforce Partnership
- Empowering Lives: The Role of Genetic Screening in Cancer Prevention
- BTIG Welcomes Christopher Boffi as New Managing Director
- Discover Intra-Cellular Therapies' Upcoming Financial Conference Call
- Canadian North Resources to Shine at International Mining Conference
- Alan Chan's ABUNDANCE: An Exciting Debut in Sci-Fi Fiction
- CleanCore Solutions Partners with Knight-Swift for Greener Future
- Cass Information Systems Delivers Strong Q3 2024 Performance
- Convex and EXL Join Forces to Enhance Operational Efficiency
- Nexalin Technology's Innovative Approach to Alzheimer's Treatment
- Investing in CPA Careers to Enhance Public Sector Services
- Innovative GAN Model from Chung-Ang University Boosts AI Capabilities
- Xometry Welcomes Roy Azevedo to Bolster Board Leadership
- MultiPlan Corporation to Host Q3 Earnings Call – Join Us!
- Verde Resources Unveils VerdePlus, Paving the Way for Green Infrastructure
- Selectis Health Strengthens Leadership with CEO Appointment
- Harnessing AI in Financial Services: Bridging Data Gaps
- Join Church's Texas Chicken® for a Spook-tacular Halloween
- Madison River Hash Company: Pioneering Quality Cannabis Products
- Susan Garcia Joins DISCO as General Counsel and CCO
- Amaanah Refugee Services Welcomes New Leadership for Growth
- Investigation Underway: Data Compromise at TransUnion Risk
- Permira's Strategic Move: Acquiring Squarespace for Growth
- Familia.AI Unveils Innovative AI App for Family Connections
- Expert Predictions Suggest Meta Platforms Could Surge 13%
- Geekplus Expands Automation Solutions for Enhanced Delivery Efficiency
- Lee Health's Virtual Nursing Program Grows with Caregility
- Elevance Health Reports $1 Billion Profit Amid Rising Costs
- EQT Exeter Enhances Portfolio with Major Industrial Acquisition
- American Industrial Partners Acquires Architectural Coatings Firm
- Obsidian Solutions Group Embarks on New Emergency Response Journey
- Bach Talk Podcast Kicks Off Exciting Second Season of Music
- Revolutionizing Document Management with AI Solutions
- Strong US Retail Sales Boost Confidence in Economic Growth
- Innovative Robots Boost Efficiency at THG Fulfil's Warehouse
- MyDirectives and National POLST Team Up for Medical Orders
- Piper Sandler Optimistic on SL Green Realty Despite Market Trends
- Grecian Delight | Kronos Pledges Significant Food Aid for Relief
- Hyatt and Peloton Partner to Elevate Guest Wellbeing Experience
- Couchbase's Capella Service Set to Transform Growth Strategy
- Desert Donuts Expands with New Franchise in Colorado
- Tredegar's Terphane Division Acquisition by Oben Group Approved
- U.S. Bancorp's Stock Analysis: Positive Growth Trends Ahead
- Discover French Cancan: Gérard Bertrand’s Innovative Wine Line
- Broadvoice Partners with CommunityWFM for Enhanced CX Solutions
- Berkshire Hills Bancorp Optimizes Operations with Strategic Sales